Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation
These results make quizartinib the first FLT3 inhibitor to demonstrate such improvement over chemotherapy in this patient population.
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.
With Emerging Oncology Therapies and Rising Patient Responsibilities, Financial Navigation Will Have a Greater Role in Cancer Care
Emerging pharmacologic therapies used for the treatment of oncology are being developed and approved at an accelerated rate.
AONN+ Navigation Metrics can be incorporated into partnerships between oncology patient navigators and physician practices.
Results 1 - 4 of 4